ES2155045T1 - Inhibicion de la quinasa raf utilizando ureas heterociclicas sustituidas con arilo y heteroarilo. - Google Patents

Inhibicion de la quinasa raf utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.

Info

Publication number
ES2155045T1
ES2155045T1 ES98963810T ES98963810T ES2155045T1 ES 2155045 T1 ES2155045 T1 ES 2155045T1 ES 98963810 T ES98963810 T ES 98963810T ES 98963810 T ES98963810 T ES 98963810T ES 2155045 T1 ES2155045 T1 ES 2155045T1
Authority
ES
Spain
Prior art keywords
substituted
group
heteroaryl
nr5r5
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES98963810T
Other languages
English (en)
Other versions
ES2155045T3 (es
Inventor
Jacques Dumas
Uday Khire
Timothy Bruno Lowinger
Holger Paulsen
Bernd Riedl
William J Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Publication of ES2155045T1 publication Critical patent/ES2155045T1/es
Application granted granted Critical
Publication of ES2155045T3 publication Critical patent/ES2155045T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Un compuesto de fórmula (I) y sus sales farmacéuticamente aceptables **fórmula** en cuya fórmula A es un heteroarilo seleccionado del grupo constituido por **fórmula** en cuyas fórmulas R1 se selecciona del grupo constituido por alquilo C3-C10, Cicloalquilo C3-C10, alquilo C1-C10 hasta per-halosustituido y cicloalquilo C3-C10 hasta per-halosustituido; B es un resto arilo o heteroarilo sustituido o insustituido, hasta tricíclico, de hasta 30 átomos de carbono con al menos una estructura aromática de 5 ó 6 miembros que contiene 0-4 miembros del grupo constituido por nitrógeno, oxígeno y azufre, en el cual si B es un grupo sustituido, está sustituido con uno o más sustituyentes seleccionados independientemente del grupo constituido por halógeno, hasta per-halosustitución, y Xn, en cuya fórmula n es 0-3 y cada X se selecciona independientemente del grupo constituido por -CN, -CO2R5, -C(O)NR5R5'', -C(O)R5, -NO2, -OR5, -SR5, -NR5R5'', -NR5 C(O)OR5'', -NR5 C(O)R5'', alquilo C1-C10, alquenilo C2-C10, alcoxi C1-C10, cicloalquilo C3-C10, rilo C6-C14, alcarilo C7-C24, heteroarilo C3-C13, alc-heteroarilo C4-C23, alquilo C1-C10 sustituido, alquenilo C2-C10 Sustituido, alcoxilo C1-C10 sustituido, cicloalquilo C3-C10 sustituido, alc-heteroarilo C4-C23 sustituido e -Y-Ar; donde X es un grupo sustituido, estásustituido conuno o más sustituyentes seleccionados independientemente del grupo constituido por -CN, -CO2R5, -C(O)R5, -C(O)NR5R5'', -OR5, -SR5, -NR5R5'', -NO2, -NR5 C(O)R5'', -NR5 C(O)OR5'' y halógeno hasta per-halosustitución; en cuyas fórmulas R5 y R5'' se seleccionan independientemente de H, alquilo C1-C10, alquenilo C2-C10, cicloalquilo C3-C10, arilo C6-C14, heteroarilo C3-C13, alcarilo C7-C24, alc-heteroarilo C4-C23, alquilo C1-C10 hasta per-halosustituido, alquenilo C2-C10 hasta per-halosustituido, cicloalquilo C3-C10 hasta per-halosustituido, arilo C6-C14 hasta per-halosustituido y heteroarilo C3-C13 hasta per-halosustituido, en cuyas fórmulas Y es -O-, -S-, -N(R5)-, -(CH2)m-, -C(O)-, -CH(OH)-, -(CH2)mO-, -NR5 C(O)NR5R5''-,-NR5C(O)-, -C(O)NR5a-O(CH2)m-, -(CH2)mS-, -(CH2)mN(R5)-, -O(CH2)m-, -CHXa -, -CXa2-, -S-(CH2)m- y -N(R5 )(CH2)m-, m = 1-3, y X a es halógeno; y Ar es una estructura aromática de 5-10 miembros que contiene 0-2 miembros del grupo constituido por nitrógeno, oxígeno y azufre que está insustituida o sustituida con halógeno hasta per-halosustitución y sustituida opcionalmente con Zn1, encuyafórmula n1 es 0 a 3 y cada Z se selecciona independientemente del grupo constituido por -CN, -CO2R5, -C(O)NR5R5'', -C(O)NR5 , -NO2, -OR5, -SR5, -NR5R5'', -NR5C(O)OR5'', -C(O)R5 , NR5 C(O)R5'', alquilo C1-C10, cicloalquilo C3-C10, arilo C6-C14, heteroarilo C3-C13, alcarilo C7-C24, alc-heteroarilo C4-C23, alquilo C1-C10 sustituido, cicloalquilo C3-C10 sustituido, alcarilo C7-C24 sustituido y alc-heteroarilo C4-C23 sustituido; en cuyas fórmulas, si Z es un grupo sustituido, estásustituido conlosuno o más sustituyentes seleccionados independientemente del grupo constituido por -CN, -CO2R5, -C(O)NR5R5'', -OR5, -SR5, -NO2, -NR5R5'' , -NR5C(O)R5'' y -NR5C(O)OR5'', y en cuyas fórmulas R2 es arilo C6-C14, heteroarilo C3-C14, arilo C6-C14 sustituido o heteroarilo C3-C14 sustituido, en cuyas fórmulas, si R2 es un grupo sustituido, está sustituido conuno o más sustituyentes seleccionados independientemente del grupo constituido por halógeno, hasta per-halosustitución, y Vn, en cuya fórmula n = 0-3 y cada V se selecciona independientemente del grupo constituido por -CN, -CO2R5, -C(O)NR5R5'', -OR5 , -SR5, -NR5R5'', -C(O)R5, -OC(O)NR5R5'', -NR5 C(O)OR5'', -SO2R5, SOR5, -NR5C(O)R5'', -NO2, alquilo C1-C10, cicloalquilo C3-C10, arilo C6-C14, heteroarilo C3-C13, alcarilo C7-C24, alc-heteroarilo C4-C24, alquilo C1-C10 sustituido, cicloalquilo C3-C10 sustituido, arilo C6-C14 sustituido, heteroarilo C3-C13 sustituido, alcarilo C7-C24 sustituido y alc-heteroarilo C4-C24 sustituido, donde, si V es un grupo sustituido, está sustituido con uno o más sustituyentes seleccionados independientemente delgrupo constituido por halógeno, hasta per-halosustitución, -CN, -CO2R5, -C(O)R5, -C(O)NR5R5'', -NR5 R5'', -OR5, -SR5, -NR5C(O)R5'', -NR5 C(O)OR5'' y -NO2; en cuyas fórmulas R5 y R5'' son cada uno independientemente como se define con anterioridad.
ES98963810T 1997-12-22 1998-12-22 Inhibicion de la quinasa raf utilizando ureas heterociclicas sustituidas con arilo y heteroarilo. Expired - Lifetime ES2155045T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99618197A 1997-12-22 1997-12-22
US996181 1997-12-22

Publications (2)

Publication Number Publication Date
ES2155045T1 true ES2155045T1 (es) 2001-05-01
ES2155045T3 ES2155045T3 (es) 2007-02-01

Family

ID=25542594

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98963810T Expired - Lifetime ES2155045T3 (es) 1997-12-22 1998-12-22 Inhibicion de la quinasa raf utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.

Country Status (29)

Country Link
EP (1) EP1056725B1 (es)
JP (1) JP4395823B2 (es)
KR (1) KR100622138B1 (es)
CN (1) CN1117081C (es)
AT (1) ATE328873T1 (es)
AU (1) AU765412B2 (es)
BG (1) BG65207B1 (es)
BR (1) BR9814361A (es)
CA (1) CA2315713C (es)
CU (1) CU23127A3 (es)
CY (1) CY1105395T1 (es)
CZ (1) CZ299836B6 (es)
DE (2) DE69834842T2 (es)
DK (1) DK1056725T3 (es)
ES (1) ES2155045T3 (es)
GR (1) GR20010300010T1 (es)
HK (1) HK1029989A1 (es)
HU (1) HUP0004426A3 (es)
ID (1) ID26328A (es)
IL (2) IL136773A0 (es)
NO (1) NO319209B1 (es)
NZ (1) NZ505845A (es)
PL (1) PL341356A1 (es)
PT (1) PT1056725E (es)
RU (1) RU2265597C2 (es)
SK (1) SK285371B6 (es)
TR (3) TR200002617T2 (es)
UA (1) UA67763C2 (es)
WO (1) WO1999032455A1 (es)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1473292A1 (en) * 1997-11-03 2004-11-03 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
ES2155817T3 (es) * 1997-12-22 2007-06-16 Bayer Pharmaceuticals Corp. Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
WO1999032111A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
CZ299156B6 (cs) * 1997-12-22 2008-05-07 Bayer Corporation Substituované heterocyklické mocoviny, farmaceutické prípravky je obsahující a jejich použití
AU2006201959B2 (en) * 1997-12-22 2008-09-04 Bayer Healthcare Llc Inhibition of Raf Kinase using Substituted Heterocyclic Ureas
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
EP1157026A1 (en) 1999-02-22 2001-11-28 Boehringer Ingelheim Pharmaceuticals Inc. Polycyclo heterocyclic derivatives as antiinflammatory agents
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
DE60014603T2 (de) 1999-03-12 2006-02-16 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
DE60023853T2 (de) 1999-03-12 2006-05-24 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Aromatische heterozyklische verbindungen als antientzündungwirkstoffe
DE60024830T2 (de) 1999-07-09 2006-06-14 Boehringer Ingelheim Pharma Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
YU9602A (sh) * 1999-08-12 2004-11-25 Pharmacia Italia S.P.A. Derivati 3(5)-amino-pirazola, postupak za njihovu izradu i njihova upotreba kao antitumornih agenasa
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
AU1623601A (en) 1999-11-22 2001-06-04 Smithkline Beecham Plc Novel compounds
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
EA006381B1 (ru) 2000-08-10 2005-12-29 Фармация Италия С.П.А. Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
WO2002044156A2 (en) 2000-11-29 2002-06-06 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
EP1392661A1 (en) 2001-05-16 2004-03-03 Boehringer Ingelheim Pharmaceuticals Inc. Diarylurea derivatives useful as anti-inflammatory agents
JP2004531571A (ja) 2001-05-25 2004-10-14 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物
EP1709965A3 (en) * 2001-07-11 2006-12-27 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediate diseases
WO2003022838A1 (en) * 2001-09-05 2003-03-20 Smithkline Beecham Plc Pyridine substituted furan derivatives as raf kinase inhibitors
ES2393900T3 (es) * 2001-12-03 2012-12-28 Bayer Healthcare Llc Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
EP2324825A1 (en) 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
PT1580188E (pt) 2002-02-11 2012-01-25 Bayer Healthcare Llc Aril-ureias como inibidores de cinases
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
US20040023961A1 (en) * 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
ATE386030T1 (de) 2002-02-25 2008-03-15 Boehringer Ingelheim Pharma 1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
JP2005537290A (ja) * 2002-07-25 2005-12-08 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
MXPA05009104A (es) 2003-02-28 2006-05-31 Bayer Pharmaceuticals Corp Derivados de urea biciclica novedosa utiles en el tratamiento del cancer y otros trastornos.
MXPA05012377A (es) 2003-05-15 2006-05-25 Arqule Inc Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38.
ATE366108T1 (de) 2003-05-20 2007-07-15 Bayer Pharmaceuticals Corp Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
US7767670B2 (en) * 2003-11-13 2010-08-03 Ambit Biosciences Corporation Substituted 3-carboxamido isoxazoles as kinase modulators
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
CA2560128A1 (en) * 2004-03-19 2005-10-06 Dipharma S.P.A. Intermediates for the preparation of pramipexole
JP2007535565A (ja) * 2004-04-30 2007-12-06 バイエル ファーマシューティカルス コーポレーション 癌の治療に有用な置換ピラゾリル尿素誘導体
US7829560B2 (en) 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
JP2008517064A (ja) 2004-10-19 2008-05-22 アークル インコーポレイテッド Ｐ３８ｍａｐキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
EP1835934A4 (en) * 2004-12-23 2010-07-28 Deciphera Pharmaceuticals Llc ENZYME MODULATORS AND TREATMENTS
GB0500435D0 (en) * 2005-01-10 2005-02-16 Novartis Ag Organic compounds
DE602006017188D1 (de) 2005-03-07 2010-11-11 Bayer Schering Pharma Ag Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
US8299252B2 (en) 2005-08-05 2012-10-30 Chugai Seiyaku Kabushiki Kaisha Pyrazolopyridine and pyrrolopyridine multikinase inhibitors
DE102005037499A1 (de) * 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
WO2007059202A2 (en) * 2005-11-15 2007-05-24 Bayer Healthcare Ag Pyrazolyl urea derivatives useful in the treatment of cancer
JP5331485B2 (ja) 2005-12-21 2013-10-30 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 癌および他の障害の処置に有用な置換ピリミジン誘導体
EP2094268A2 (en) 2006-05-26 2009-09-02 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US20100150863A1 (en) 2006-12-20 2010-06-17 Bayer Pharmaceuticals Corporation Hydroxy methyl phenyl pyrazolyl urea compound useful in treatment of cancer
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
CA2682162C (en) 2007-04-02 2016-05-10 Renovis, Inc. Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
AU2008242767A1 (en) 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
KR20100117686A (ko) 2008-02-29 2010-11-03 어레이 바이오파마 인크. 피라졸[3,4-ｂ]피리딘 ｒａｆ 저해물질
EP2265608A2 (en) 2008-02-29 2010-12-29 Array Biopharma, Inc. Raf inhibitor compounds and methods of use thereof
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
PE20110598A1 (es) 2008-10-02 2011-08-31 Respivert Ltd Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
US8299073B2 (en) 2008-12-11 2012-10-30 Respivert Ltd. P38 MAP kinase inhibitors
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
JP5787976B2 (ja) 2010-04-08 2015-09-30 レスピバート・リミテツド Ｐ３８ｍａｐキナーゼ阻害剤としてのピラゾリルウレア
JP5789259B2 (ja) 2010-07-16 2015-10-07 協和発酵キリン株式会社 含窒素芳香族複素環誘導体
US20130183268A1 (en) 2010-07-19 2013-07-18 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
BR112014007694B1 (pt) 2011-10-03 2022-09-27 Respivert Limited Compostos de 1-(3-(tert-butil)-1-(p-tolil)-1h-pirazol-5-il)-3-(4-((2-(fenilamino) pirimidin-4-il)óxi) naftalen-1-il)ureia, seus usos, composição e formulação farmacêutica compreendendo os mesmos
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
KR20140011780A (ko) 2012-07-19 2014-01-29 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
WO2014140582A1 (en) 2013-03-14 2014-09-18 Respivert Limited Kinase inhibitors
WO2015066490A1 (en) 2013-10-31 2015-05-07 Ohio University Prevention and treatment of non-alcoholic fatty liver disease
EA034927B1 (ru) 2014-02-14 2020-04-07 Респайверт Лимитед Ароматические гетероциклические соединения как противовоспалительные соединения
US10023567B2 (en) 2014-07-18 2018-07-17 Ohio University Imidazole and thiazole compositions for modifying biological signaling
IL277071B1 (en) 2018-03-08 2024-03-01 Incyte Corp Aminopyrizine diol compounds as PI3K–y inhibitors
CN108484587A (zh) * 2018-06-03 2018-09-04 刘思良 一种Raf激酶抑制剂及其在癌症治疗中的应用
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
RS65058B1 (sr) 2019-12-30 2024-02-29 Deciphera Pharmaceuticals Llc Formulacije inhibitora amorfne kinaze i postupci njihove primene
BR112022013169A2 (pt) 2019-12-30 2022-09-13 Deciphera Pharmaceuticals Llc Composições de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofeil)-3-fenilurea
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162360A (en) * 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
GB9302275D0 (en) * 1993-02-05 1993-03-24 Smithkline Beecham Plc Novel compounds
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
GB9623833D0 (en) * 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
ATE399007T1 (de) * 1997-05-23 2008-07-15 Bayer Pharmaceuticals Corp Raf kinase hemmer
WO1999023091A1 (en) * 1997-11-03 1999-05-14 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
ES2155817T3 (es) * 1997-12-22 2007-06-16 Bayer Pharmaceuticals Corp. Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.

Also Published As

Publication number Publication date
BG65207B1 (bg) 2007-07-31
NO319209B1 (no) 2005-06-27
HK1029989A1 (en) 2001-04-20
CZ299836B6 (cs) 2008-12-10
WO1999032455A1 (en) 1999-07-01
SK285371B6 (sk) 2006-12-07
DK1056725T3 (da) 2006-10-02
CA2315713C (en) 2011-02-01
IL136773A (en) 2006-10-31
ES2155045T3 (es) 2007-02-01
UA67763C2 (uk) 2004-07-15
AU1905599A (en) 1999-07-12
JP2001526269A (ja) 2001-12-18
RU2265597C2 (ru) 2005-12-10
IL136773A0 (en) 2001-06-14
CZ20002349A3 (en) 2001-05-16
NO20003231D0 (no) 2000-06-21
PL341356A1 (en) 2001-04-09
CN1117081C (zh) 2003-08-06
NO20003231L (no) 2000-08-22
ATE328873T1 (de) 2006-06-15
SK9622000A3 (en) 2001-01-18
KR100622138B1 (ko) 2006-09-13
CY1105395T1 (el) 2010-07-28
TR200100917T2 (tr) 2001-07-23
NZ505845A (en) 2003-10-31
EP1056725A4 (en) 2001-02-07
BR9814361A (pt) 2001-11-27
DE1056725T1 (de) 2001-06-07
EP1056725A1 (en) 2000-12-06
CN1283192A (zh) 2001-02-07
DE69834842D1 (de) 2006-07-20
DE69834842T2 (de) 2007-05-10
EP1056725B1 (en) 2006-06-07
CU23127A3 (es) 2006-04-18
KR20010033513A (ko) 2001-04-25
AU765412B2 (en) 2003-09-18
GR20010300010T1 (en) 2001-03-30
CA2315713A1 (en) 1999-07-01
JP4395823B2 (ja) 2010-01-13
PT1056725E (pt) 2006-09-29
HUP0004426A3 (en) 2001-07-30
ID26328A (id) 2000-12-14
BG104598A (en) 2001-02-28
HUP0004426A2 (hu) 2001-05-28
TR200100918T2 (tr) 2001-06-21
TR200002617T2 (tr) 2000-11-21

Similar Documents

Publication Publication Date Title
ES2155045T1 (es) Inhibicion de la quinasa raf utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
ES2153340T1 (es) Inhibicion de la quinasa raf utilizando ureas heterociclicas sustituidas.
AR041719A1 (es) Derivados de metilenurea como inhibidores de la raf-quinasa
AR043047A1 (es) Derivados de glicinamida
CO6190515A2 (es) Derivados indolicos con anilo unido en las posiciones 4,5 y sus metodos de uso
AR082886A1 (es) Compuestos y composiciones farmaceuticas que los contienen
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
AR035310A1 (es) Difenilureas substituidas con omega carboxiarilo como inhibidores de raf quinasa; sus composiciones farmaceuticas y un metodo para el tratamiento del crecimiento de celulas cancerosas
AR045033A1 (es) Derivados de malonamida, metodo de obtencion y composiciones farmaceuticas que los contienen.
ES2195933T3 (es) Nuevos derivados de flavonas, xantonas y cumarinas.
CO5690577A2 (es) Derivados de imidazoquinolina como ligandos receptores de adenosina a3
ES2061663T3 (es) Derivados de carbamoilpirrolidina, su uso y preparacion.
RU93051531A (ru) Производные 7-изоиндолинилхинолона и 7-изоиндолинилнафтиридона
AR043757A1 (es) Derivados de oxamida utilizados como inhibidores de la raf-quinasa
DK1078928T3 (da) Pyridinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
AR036301A1 (es) Compuestos antidiabeticos, composiciones farmaceuticas, procedimiento de preparacion de estos y tratamiento utilizando los mismos
AR048484A1 (es) Derivados de diacilhidrazina, su uso como inhibidor de raf quinasa y composiciones farmaceuticas que los contienen
FI860111A (fi) Terapeutiska medel.
CO5040004A1 (es) 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores
ES2317103T3 (es) Derivados de c-ciclohexilmetilamina sustituidos.
AR035486A1 (es) Compuestos de pirazol, composiciones farmaceuticas y metodos para modular y/o inhibir la actividad de erab/hadh2
DE3877386T2 (de) Antikrebsverbindungen.
AR043487A1 (es) Heterociclos fusionados de pirimidina y usos de los mismos
RU2007135745A (ru) АКТИВАТОР δ- РЕЦЕПТОРА, АКТИВИРУЕМОГО ПРОЛИФЕРАТОРОМ ПЕРОКСИСОМЫ
AR008228A1 (es) Derivados aromaticos sustituidos con un radical de ribosa, su procedimiento de preparacion, compuestos intermediarios para su exclusivo uso en dicho procedimiento, medicamentos y composiciones farmaceuticas.